  Although matrix metalloproteinases (MMPs) are implicated in the regulation of
numerous physiological processes, evidences of their pathological roles have
also been obtained in the last decades, making MMPs attractive therapeutic
targets for several diseases. Recent discoveries of their involvement in
central nervous system (CNS) disorders, and in particular in Alzheimer's
disease (AD), have paved the way to consider MMP modulators as promising
therapeutic strategies. Over the past few decades, diverse approaches have been
undertaken in the design of
